Regeneron Pharmaceuticals Inc (REGN) Buy,…

Home

Daily Stock Opinions and Ratings

Regeneron Pharmaceuticals Inc (REGN)

781.49

-11.77 (1.48%)

as of Sep 11, 2026, 8:00:00 pm Market Open.

67 watching

Investor Insights

Sep 11, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Regeneron Pharmaceuticals Inc has recently faced criticism following disappointing results from a cancer drug trial, which had raised expectations for success. The negative news has led to a significant drop in its stock price, falling 10% in a single day, generating concerns over potential future downgrades from analysts. Despite this setback, it is noteworthy that the stock has seen a remarkable rise of 53% over the last six months, indicating that it had been on a positive trajectory prior to this incident. This dual narrative of acute short-term trouble contrasted with longer-term gains paints a complex picture for investors, asserting the need for careful evaluation of the stock's potential moving forward.

Consensus

Mixed

Valuation

Overvalued

Similar

AMGN

TOP PICK

A higher-risk/return play. This biotech has several core products generating good free cash flow. They’re partnering with Sanofi on Dupixent to treatment severe atopic dermatitis and potentially severe asthma. They also have another drug to treat specific eye diseases. REGN boasts various late-stage drug trials. Regeneron is a new Top Pick for us, driven by the valuation having compressed significantly on concerns over U.S. Medicare Part B drug pricing policy proposals. We believe these are more than reflected in the current price.Their dermatitis drug is getting traction. This stock has been beat up for the wrong reasons. This (Analysts’ price target is $389.38)

BUY

Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.

PAST TOP PICK

(Past Top Pick on August 8, 2017, Down 40%) Sold his at a stop loss before things got worse. You must be ruthless in selling your losers or you'll suffer even more downside.

TOP PICK

He likes biotech as a space, and it has recently re-accelerated. This company has a number of key drugs. Their major drug is Eylea for macular degeneration, a multi-, multi-billion-dollar drug. However, they have a newer drug, which is aimed at the allergy market, which could potentially be a $10 billion drug. This company will double its earnings in the next 3 years and is not dependent on one product. (Analysts’ price target is $438.)

HOLD

Loves the biotech sector right now. If he had to invest money in one sector right now, it would be Biotechs. He likes this company. They are positioned very well.

Showing 31 to 35 of 35 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Capital Wealth Planning

Greg Newman

Scotia Wealth Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Regeneron Pharmaceuticals Inc (REGN)